Background: This clinical study was conducted to compare pharmacokinetics of eperisone and aceclofenac of HCP1104, a new fixed dose combination drug with those in co-administration of eperisone 50 mg and aceclofenac 100 mg. The study used a partial replicated study design to characterize intra-subject variability of eperisone when co-administrated with aceclofenac. Methods: A partial replicated crossover design was employed in 30 subjects. Each subject received a single dose of co-administration of eperisone 50 mg and aceclofenac 100 mg on two occasions and a single dose of 1 capsule of HCP1104. Blood samples were obtained for 24 hrs after dosing, and plasma was assayed for eperisone and aceclofenac by Liquid chromatography-electrospray ionization-mass spectrometry. Results: Using an average bioequivalence criterion, the 90 % confidence limits for Ln-transformed C max and AUC last for aceclofenac fell wihin the acceptable range of 80 -125 %. Point estimates of eperisone AUC last and C max were 1.0152 and 1.0490, respectively and the 90 % confidence interval for C max was 0.8499 -1.3025. The within-subject coefficient of variation of C max for the reference was 50.198 %. Acceptance range for eperisone C max based on new bioequivalence guidance for highly variable drugs was extended to 0.6984 -1.4319. Conclusion: The extent of exposure and rate of absorption of both eperisone and aceclofenac with a single dose of HCP1104 capsule were equivalent to those with co-administration of a marketed eperisone 50 mg tablet and a marketed aceclofenac 100 mg tablet under fasting conditions in healthy adult males.
Blood creatine phosphokinase increased 0(0%) 0(0%) 1(3.33%) 1(3.33%) Eosinophil count increased 0(0%) 1(3.33%) 0(0%) 1(3.33%) Injury, poisoning and procedural complications Excoriation 0(0%) 1(3.33%) 0(0%) 1(3.33%) Gastrointestinal disorders Diarrhoea 0(0%) 1(3.33%) 0(0%) 1(3.33%) General disorders and administration site conditions Pyrexia 0(0%) 1(3.33%) 0(0%) 1(3.33%) * R: Reference, co-administration of eperisone 50 mg and aceclofenac 100 mg, 1: first administration of reference, 2: replicated administration of reference. 
